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ABSTRACT
Excess production and secretion of very low-density lipoprotein (VLDL) by the liver into the
circulatory system is directly related to atherosclerosis, a chronic cardiovascular disease that
threatens the lives of many worldwide and continues to be a leading cause of death in the United
States. The rate-limiting step in VLDL secretion is its transport from the site of biogenesis, the
hepatic endoplasmic reticulum to the cis-Golgi. This step is mediated by a specialized ERderived vesicle, the VLDL transport vesicle (VTV). Upon exit of the ER the VTV targets, fuses
and delivers VLDL into the lumen of the Golgi. The targeting and fusion of the VTV with the
Golgi is facilitated by specific set of soluable N-ethylmaleimide sensitive factor attachment
protein receptor (SNARE) proteins that form a SNARE complex, which is required for the VTVGolgi fusion and thus delivery to the Golgi. Data from our laboratory indicates that the formation
of the SNARE complex requires cytosolic factors. Through the purification of liver cytosol,
chromatographic steps, detailed mass spectrometry, immunodepletion and western blotting data
it was identified that the protein necessary for SNARE complex formation is Hsc-70. Although
Hsc-70’s identification is significant, the role it plays in SNARE complex formation for VTV Golgi fusion is a predicament and yet to be unraveled. In this study we performed a series of coimmunoprecipitation reactions to identify its role in SNARE-complex assembly. Using western
blot data we confirmed binding of Hsc-70 with Sec22b, the v-SNARE on the VTV. Moreover,
we confirmed the interaction of Hsc-70 with t-SNAREs, (syn5, rBet1 and GOS28) on the Golgi
membrane. Removal of Hsc-70 from the liver cytosol resulted in significant reduction of
SNARE-complex formation. Ultimately, the identification proteins involved in the process of
VLDL delivery to the Golgi would offer therapeutic targets to control VLDL secretion into the
blood by the liver.
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CHAPTER ONE: INTRODUCTION
Atherosclerosis & Lipid Metabolism

Atherosclerosis is a disease that is characterized by the hardening of the arteries due to
the formation of plaque from excess cholesterol, fat and other substances [1]. The risks to
develop atherosclerosis are related to the over production and secretion of a lipoprotein known as
very low-density lipoprotein (VLDL) into the blood by the liver. The biogenesis of VLDL is
crucial for lipid metabolism thus modulating its synthesis and secretion from the liver would
offer a gateway to develop better treatments for plaque formation in arterial wall.
The liver is responsible for controlling lipid metabolism in mammalian species. A large
portion of lipids entering the liver is contributed from non-esterified free fatty acids (NEFA),
which are the major components of triglycerides, the major supply of energy and fat in our
tissues. The potential sources of free fatty acids that enter hepatocytes also liver cells include:
peripheral fats stored in adipose tissue, dietary fatty acids which enter the liver through
chylomicron remnants and through the intestine via the portal vein [2]. Once NEFAs are up
taken by the liver, their fate is determined based on energy requirements of the body,
consequently excess influx of free fatty acids leads to the repackaging of triglycerides to form a
VLDL particle that will be excreted from the liver into the blood. Once in the blood the VLDL
particle is further metabolized into IDL (intermediate density lipoprotein) and LDL (low density
lipoprotein) [3]. LDL particles contain a large amount of cholesteryl ester, which undergo
oxidation when taken up by endothelial cells of blood vessels and thereby accelerate the
formation of plaque in arteries [4]. Subsequently, production of VLDL directly contributes to
the plaque formation of atherosclerosis. Herein, research will describe the role of a 70 kDa
protein recently identified as being involved in the biogenesis of VLDL.
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Biogenesis of VLDL

Lipoproteins are spherical particles utilized to transport lipids and lipophilic substances
into circulation [5]. The VLDL lipoprotein is composed of a core of neutral lipids, which is
surrounded, by phospholipids, cholesterol, high percentage of triacylglycerides, and specific
apolipoproteins [6]. An apolipoprotein is a protein that combines with lipids such as triglycerides
and cholesterol [7].

Amongst the various types of apolipoproteins, apolipoprotein B100

(apoB100) is present in the liver and provides structural stability thus being an essential
component in the formation of the VLDL and its circulating metabolites LDL and IDL particles
[8]. Furthermore, Apolipoprotein B is found in two forms: the Apo B100 and its truncated
version Apo B48. Although they come from the same gene, ApoB100 is the full version made in
the liver with a molecular weight of 550 kDa and 4536 amino acids. While ApoB48 is mainly
found in the intestines, and mostly serves as a structural protein for chylomicrons, it is composed
of only 48 percent of ApoB100 due to a posttranscriptional editing of the apoB messenger
ribonucleic acid (mRNA) resulting in the switching of a glutamine (CAA) to a stop codon
(UAA) [9, 10].
The formation of VLDL takes place in the lumen of the rough endoplasmic r.eticulum
(rER) in hepatocytes. However, the assembly of the VLDL lipoprotein is broken down into two
steps, first is the synthesis of the primordial VLDL particle by the partial lipidation of ApoB100
in the lumen of the hepatic rough ER, a process facilitated by microsomal triglyceride transfer
protein (MTP). Conversely, the growing polypeptide of ApoB100 acquires a proper folding
conformation in which the hydrophobic side will associate with lipid and the hydrophilic side of
the lumen will interface with the aqueous environment of the cytosol. In the second step, neutral
lipids or triglycerides (TAG) are added to the nascent VLDL thus forming a rich-TAG VLDL
particle [11-13]. Once the nascent VLDL is formed in the lumen of the rER it will travel to the
hepatic cis-Golgi apparatus to ensue it’s processing for further maturation. Although the site of
VLDL maturation in the hepatocyte is subject to debate, some studies reveal the ER as its site of
maturation, yet others propose the cis-Golgi as the final site for VLDL maturation thus being
congruent with several studies, which indicate that upon VLDL-ApoB100 particle delivery to the
2

cis-Golgi, it undergoes phosphorylation and glycosylation obtaining endoglycosidase H
resistance [14].
VLDL Transport Vesicle (VTV)

The production of ER-derived vesicles and their movement to the cis- Golgi serves as the
rate limiting step for the secretion of VLDL from the liver to the bloodstream [14]. According to
Siddiqi et al [14], the VLDL particle can easily get lipid hydrolyzed in the cytosolic environment
therefore, a specific mechanism must take place in order to protect the VLDL particle from the
potent proteinases found in the cytosol. Furthermore, Several features indicate that proteins and
lipids exit the ER in distinct manners. The protein transport vesicle (PTV), a vesicle synthesized
in the ER and responsible of transporting nascent proteins to the Golgi, is mediated by the
recruitment of a group of proteins called coat protein complex II (COP-II) consisting of five
subunits: Sar1, Sec23/24 and Sec13/Sec31 [15]. However, the 60-80nm size of PTVs denotes a
limitation to properly accommodate the VLDL particle thus posing a predicament in its transport
to the Golgi. As a result data from our laboratory and Fisher’s group [16], suggested that the
specialized vesicle (VTV), which is morphologically and biochemically different than any other
ER derived vesicle, enables the intracellular transport of VLDL from the ER to the cis-Golgi [10,
12]. VTVs range in size of 100-120nm, apt to comfortably fit the 90nm VLDL cargo, data
collected from Siddiqi et al [14] also show that in addition to VTVs concentrating ApoB100, a
VLDL marker protein, it is also protected from proteolysis as seen on experiments with
proteinase K treatment. Finally, VTVs also concentrate the COPII proteins, a required complex
for vesicles having the Golgi as their destination [10, 14]. Ultimately, the identification of
proteins essential for selecting and packing VLDL into the VTV remain to be identified.
Coat Protein Complex II (COPII)

Although VTVs are notably different than PTVs, they also possess COPII dependent
mechanism to transport their cargo [16]. COPII coat is used to shape lipid membranes to
3

produce transport vesicles by the recruitment of cytosolic proteins [17]. COPII assembly is
broken down into four steps, the first step begins by the recruitment and conversion of Sar 1GDP to Sar 1-GTP by Sec12, a guanine nucleotide exchange factor for Sar 1 found in the ER
membrane. The second step takes place when the heterodimeric complex Sec23/24 is recruited,
this complex plays a role in cargo selection and forms the inner coat of COPII. Step three arises
when Sar1- Sec23/24 attaches to the ER membrane thus forming a pre-complex which will in
turn recruit both Sec 13 and Sec 31 as a heterodimer, Sec13/31 will form the outer layer of
COPII and signal membrane deformation leading to vesicle formation. Finally, the fourth step
takes place when GTP is hydrolyzed and as a result Sar1 detaches from the ER membrane
initiating the release of the newly formed vesicle [10, 18].

SNARE Complex formation

The presence of intracellular compartments is a salient feature of eukaryotic cells.
Trafficking amongst cellular compartments is mediated by transport vesicles, thus specificity for
accurate content delivery is facilitated by proteins that regulate the budding, target selection and
fusion of membranes. It has been widely agreed that specific soluable N-ethylmaleimidesensitive attachment receptor proteins (SNARE proteins) direct transport vesicles to their target
membranes. SNARE proteins are membrane proteins that contain motifs of 60 to 70 residues in
length [19, 20]. These SNARE motifs form specific domains-heptad repeats of hydrophobic
residues that mainly function to form a parallel α-helical structure necessary to bring the
membranes in close proximity thereby allowing fusion to occur. Since their discovery SNARE
proteins are generally known to participate in fusion and docking of membranes therefore being
responsible for the specificity of intracellular transport [21, 22]. In VLDL transport the VTV
buds off the ER membrane and travels to the Golgi where it will first dock and eventually fuse
with the cis-Golgi membrane releasing its cargo- the VLDL-ApoB100 particle.
In intracellular membrane fusions the SNARE pin of four member-α-helix coiled is
formed by the contribution of a single SNARE motif by each of the four SNAREs. Usually three
4

motifs are contributed by one bilayer and one motif is contributed by the opposing bilayer. [3,
23, 24]. Each SNARE complex contains a central polar layer where each of the SNARE motifs
donates a hydrophilic residue consisting of one arginine (R) and three glutamine (Q) side chains
[19]. It has been described by Fasshauer et al. [25] that vesicles localize the (R) residue whereas
the target layer contains the three (Q) side chains and are termed Q-SNAREs. In addition, the QSNAREs are further divided into Qa-Qb and Qc SNAREs donating each one motif and the RSNARE contributing another motif forming the SNARE pin or SNARE complex. Furthermore,
The association of the vesicular membrane and target membrane by the Q-SNAREs and RSNARE is mediated by the so called zippering hypothesis where the complex is formed in an
orderly manner forming a zipper from N-terminus of the motifs to the C-terminus conversely the
zippering is essential for membrane fusion to take place [21, 26].
Ultimately, data from our laboratory has identified Sec22b to be present on the surface of
the VTV acting as the v-SNARE or R-SNARE, and GOS28, Rbet1, Syntaxin5 (Syn5) as the
three cognate Q-SNAREs on the target membrane, which in this case is the cis-Golgi [3]. Once
docking and fusion takes place, the mature VLDL particle is released into the lumen of the Golgi
where it will be further glycosylated and phosphorylated to then travel to the plasma membrane
where it will be expelled to the circulation. However, the mechanism post-Golgi VLDL transport
remains to be identified.

Hypothesis and Specific Aim

The nascent VLDL is directed towards the cis-Golgi membrane by the VTV. A specific
set of SNARE proteins are integrated in the membrane of the VTV upon budding of the
endoplasmic reticulum and bind to t-SNAREs found in the cis-Golgi, forming a SNARE
complex, which facilitate the targeting of transport vesicles and mediate the fusion/docking of
VTV with the cis-Golgi membrane. The association of the SNAREs to bring the membranes in
close proximity with out the use of energy-ATP (adenosine-5'-triphosphate) is denoted as the
docking whereas fusion is the physical interactions of the opposing membranes and the release of
5

the cargo. Once this specific step takes place VLDL is released into the Golgi lumen. As a
result, we hypothesized that in order for SNARE complex to form between the VTV and cisGolgi cytosol is required. Unpublished data from the laboratory indicate that this important step
requires cytosolic proteins. In order to separate proteins in cytosol, Fast Liquid Chromatography
was employed, cytosolic fractions were collected and tested until the putative proteins were
determined amongst these, Hsc-70, (Siddiqi et al; unpublished data) a 70 kDa cytosolic protein
that seems to plays an important role in VTV Golgi fusion complex. Hsc-70 is a member of the
heat shock protein family that acts as an ATPase as well as a chaperone protein in secretory
pathways in addition Hsc-70 has been known to take part in ER to Golgi transport [24, 27].
Conversely, its form of action in regulating the fusion of VTV’s with the Golgi’s lumen remains
enigmatic. Thus, the aim of this study is to identify how Hsc-70 plays a role in SNARE complex
formation for VTV Golgi-fusion. In sum, the identification of protein(s) involved in the process
of VLDLs synthesis would offer potential targets for their inhibition and hence, serve as a
potential control for VLDL secretion from the liver.
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CHAPTER 2: EXPERIMENTAL METHODS
Materials

ECL (enhanced chemiluminescence) reagents were obtained from GE Healthcare. Mouse
monoclonal antibodies anti-Sec22b and anti syntaxin5 anit-rabbbit polyclonal were purchased
from Santa Cruz Biotechnology. Mouse anti-GOS28 antibodies were obtained from StressGen
Biotechnologies (Victoria, Canada) Goat anti-rabbit IgGs agarose beads were purchased from
Sigma Chemical Co. (St. Louis, MO) [12]. Western Blot, Electrophoresis and immunoblotting
reagents were produced from Bio-Rad (Hercules, CA) [12]. [14C] Oleic acid, [3H] Oleic acid and
[3H] Leucine were procured from PerkinElmer Life Sciences [3]. The liver used for experiments
is from the Sprague-Dawley rats attained from Harlan (Indianapolis, IN).

Bradford Assay- Protein Quantification

Protein concentration for cytosol, ER and Golgi was calculated using the Bradford assay
procedure. The general procedure is as follows: seven glass tubes are acquired and labeled. One
tube is the blank used to calibrate spectrophotometer, three are labeled standard and the other
three tubes contain different amount of the specific sample. The blank is filled with 100 µl of
dH2O; the three standards are prepared by using 10µl, 20µl and 40µl of 1mg/mL of Bovine
Serum Albumin (BSA) and 90µl, 80µl and 60µl of dH2O respectively. The sample tubes were
made by using 1:10, 2:10 and 4:10 dilutions. Moreover, five milliliters of BIO-RAD dye is used
however, the BIO-RAD dye is first prepared by employing a 1:4 dilution. Likewise, when the
standard and sample tubes are prepared, five milliliter of BIO-RAD dye is added to each tube
including the blank, each tube is vortexed and kept in incubation for five minutes. Finally, each
tube is transferred to a cuvette and placed on the DU 800 spectrophotometer where it will be read
at 590nm, the wavelength employed to read protein concentration. The blank is placed first to
calibrate the machine following with the lowest to highest concentrated standard thus a graph is
7

acquired using a computer software system. Next the sample tubes are placed one at a time again
from lowest to highest concentrated sample, once the results for each is determined the
concentration is calculated.

(SDS-PAGE) Sodium Dodecyl Sulfate Polyacrylamide gel electrophoresis

The running buffer used for the experiments is 12% and the stacking gel used is 4%. The
percentage of the gel is determined on the amount of acrylamide used as well as size of proteins
of interest. The higher the percentage of acrylamide the smaller the pores on the gel thus
acquiring a better separation of the proteins. The 12% running buffer is made first by using
3.4mL dH2O, 2.5mL of running gel buffer, 4.0mL of acrylamide; before adding SDS the
chemicals are mixed by employing a vortex to create a homogeneous mixture. Next, 0.1mL of
SDS is added along with 50µl of APS and 5µl of TEMED to allow the polymerization reaction to
occur. With a 5mL pipette the running gel is added to a glass cassette where it stays on an
incubation time of 45 minutes thus 50µl of butanol is added to prevent the gel from drying upon
polymerization. To make the 4% stacking gel 6.1mL of dH2O, 1.3mL of acrylamide and 2.5mL
of stacking gel buffer are placed together in 50mL conical tube and vortexed, immediately after
mixing 0.1mL of SDS is added along with 50µl of APS (ammonium persulfate) and 10µl of
TEMED (tetramethylethylenediamine) is added last so the polymerization reaction can begin.
The conical tube is mixed eight times slowly to avoid the production of bubbles and then using a
5mL pipette, the mixture is placed on the same glass cassette as the running gel and a comb is
used to create the wells where the samples will be added.
The samples are prepared using Laemmli 2x buffer which is made to solubilize the
protein samples, likewise the 2X buffer is made by using 190µl of laemmli sample buffer (LB)
and 10µl of B-mercaptoethanol, along with PBS (phosphate-buffered saline) and the desired
sample concentration, the samples are boiled for five minutes to disrupt the bonding and
linearize the proteins. After boiling the samples the Precision plus protein marker along with the
samples added to their respective well on the stacking gel and the cassette is placed on tank
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buffer and hooked to the Fisher Scientific FB300 machine where the current is programmed to
run constantly at 21mA for approximately ninety minutes. The proteins travel through the pores
of the gel and are separate based on their size. When the gel is finished running, it is taken out of
the cassette and transferred to a nitrocellulose membrane where a “sandwich” is formed using
two sponges and blotting paper. The assembly is placed in transfer buffer and kept at 4°C at
constant voltage and 51mA over night.
Blocking Procedure

Once the transfer is complete, the nitrocellulose membrane is washed twice with PBS-T
for five minutes. While washing is taking place, 10% milk is prepared; 5 grams of milk are
weighed and 50mL of PBS-T is used to dissolve the milk. The membrane is labeled with pencil
and incubated under the 10% milk for at least five hours. The blocking is essential since it
prevents non-specific binding while the Western blot takes place.
Final step: Western Blot

Once the blocking is completed, the membrane is washed twice for five minutes with
PBS-T (PBS with 0.05% Tween20) and the primary antibody is added. The primary antibody is
made in 30mL PBS-T 0.3g 1% Bovine Serum Albumin (BSA) and 50µl (10µg) of desired
antibody. The primary antibody is added to the membrane and incubated overnight. Next the
membrane is washed with PBS-T and a secondary antibody is added to the membrane to add
specificity. The secondary antibody is made by using 5% (w/v)- 0.5g of non-fat milk, 50 mL of
PBS-T and 3µl of either (anti-rabbit, anti-goat, anti-mouse). Furthermore, the secondary is added
and the membrane is placed on incubation for one hour. Upon incubation the membrane is
washed with PBS-T three times for five minutes and two times with PBS to remove non-specific
binding. Finally, the detection of the proteins on the membrane is acquired by exposing the
membrane to ECL reagents displaying the results in a Biomax film.
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Stripping Buffer

To utilize the nitrocellulose membrane more than once and test with different antibodies,
the membrane needs to be “stripped” meaning the previous antibody binding to the membrane
must be removed. First the membrane is washed twice with PBS-T and twice with PBS each
wash in five minutes intervals. , the stripping buffer is prepared, first weigh 0.38g of TRIS and
1g of SDS dissolve and in a 50mL conical tube filled with 45mL of dH2O. Subsequently, using
different concentration HCL and NAOH adjust the pH to 6.7, once the desired pH is reached fill,
to 50mL and add 350µl of B-mercaptoethanol. Add the stripping buffer to the nitrocellulose
membrane and incubate at 60°C for 40 minutes. Preceding incubation, wash the membrane four
times in five minutes intervals with PBS-T. Once washings are finalized the membrane is ready
to be blocked again.

Procedure of Radiolabeled Hepatic Endoplasmic Reticulum

The Endoplasmic Reticulum is doubly labeled with [H3] and [C14] or singly labeled with
[C14] [3, 14]. The 4-5g liver obtained from Sprague-Dawley rats attained from Harlan
(Indianapolis, IN) is cut up into small pieces (3mm x 5mm x 0.5mm) and washed with ice cold
0.25M sucrose in 10mM Hepes buffer with pH of 7.2 and incubated with [H3] Leucine and
albumin-bound [C14]oleate for 30 minutes at 37°C. To remove excess [H3] Leucine and
[C14]oleate it is washed with PBS encompassing 2% (w/v) BSA [3]. The plasma membrane must
be disrupted therefore the liver is placed in a buffer solution and homogenized in a Parr bomb at
6210 kPa for 40 minutes. The ER is then separated from the other cellular organelles using a step
sucrose gradient that must be repeated to obtained a purified portion of ER. Finally, to prove the
purity of the ER sample, the ER is tested for calnexin- a ER marker protein and also tested for
GOS28 and r-BET1, proteins that serve as markers for the cis-Golgi and lysosomes respectively
[3].

10

Hepatic Cytosol

The cytosol is prepared from hepatic cells obtained from rat liver. The cytosol is acquired
from the same homogenate mixture explained previously. Following the centrifugation step, the
PNS (post-nuclear supernatant) is further centrifuged at 100,000g for 90 minutes at 4°C
subsequently the supernatant collected is the cytosol [14]. In the next step, the cytosol is dialyzed
to remove ATP and GTP, conversely the cytosol is placed against an ice cold dialysis buffer
solution for 6 hours at 4°C, and further concentrated with a Centricon filter [14].
Hepatic Golgi apparatus
The Golgi has two faces the cis and trans side hence in our laboratory both the cis and trans
Golgi are non-radiolabeled and isolated from the rat liver that it is cut into pieces (3mm x 5mm x
0.5mm). The pieces are homogenized to disrupt the plasma membrane thus allowing the
separation of cell organelles through a sucrose step gradient used to isolates organelles based on
different densities by centrifugation. Finally, the purity of the Golgi is determined on the basis of
resident proteins through Western blotting.
Co-Immunoprecipitation

For the Immunoprecipitation technique, we used 170µl of ER (1mg of ER protein), 50µl
of PBS, added 10µl of TritonX to solubilize the membrane of the ER and wait until mixture turns
clear. Next add 50µl of PBS, 5µl of 10% (w/v) SDS, 5µl of 10% TritonX , 20-30µl of desired
antibody and leave sample in four hour incubation. Meanwhile, pipette 50µl of agarose beads
and washed with PBS twice for five minutes. Subsequently, after the four hour incubation add
the supernatant from previously made sample to the beads and let it spin in incubation at 4°C
overnight. Preceding incubation the desired antibody is complexed to the beads; therefore the
beads are washed with PBS to remove any unbound protein. The 2X Laemmli buffer was added
to the beads and these were boiled for five minutes, vortexed and the supernatant was removed
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and loaded into the gel. Finally, immunoprecipitated proteins are separated through SDS-PAGE,
transblotted into a nitrocellulose membrane and detected through the use of specific antibodies.

VTV- Golgi Docking Assay

The in-vitro docking of VTV with cis-Golgi was accomplished by incubating VTVs with
cis-Golgi along with Adenosine triphosphate, EDTA (Ethylenediaminetetraacetic acid) and
cytosol. Once incubation is complete the undocked and docked VTVs are separated based on
their densities on sucrose step gradients explained in more detailed in Siddiqi et al [3, 14]. For
my interest, I aspirated the VTVs associated with the cis-Golgi with the purpose of isolating the
SNARE complex. The VTV-Golgi complexes are solubilized and incubated overnight with
rabbit agarose beads. Upon completion of incubation, the beads are washed to remove unbound
protein. Lastly, the unbound protein will be assessed using protein assay following Western
blots.

12
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CHAPTER THREE: RESULTS
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Figure 1. In vitro VTV-Golgi fusion-complex formation

The objective of this experiment is to show the significance of cytosol in the SNARE complex
formation for VTV-Golgi association. To carry out these experiments an in vitro docking assay
was developed. Docking is the event that takes place when there is an associating of the VTV
with cis-Golgi, a step required for fusion. In the above results Bar 1 indicates that VTVs interact
with the cis-Golgi upon incubation at 4°C in the presence of cytosol and in the absence of ATPMg2+. However, as seen on bar 2 the association of VTV with Golgi was reduced when
incubation is done at 4°C with ATP-Mg2+ in the absence of cytosol, this indicates that cytosolic
factors are needed for VTV-Golgi docking. In Bar 3 we observed the effect of ATP-Mg2+,
which suggests that in the presence ATP-Mg2+ VTV-Golgi docking d.p.m count show a reduced
docking activity. Finally bar 4 shows the incubation of VTVs with Golgi in presence of cytosol
and ATP-Mg2+ at 37°C, the conditions favorable for the VTV-Golgi fusion event.
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Figure 2 (A) Fusion-complex formation activity of various pure recombinant proteins identified by tandem
mass spectrometry:

Formation of the SNARE complex requires cytosol however; the cytosolic factors remain to be
identified. To identify cytosolic factors we performed a series of chromatographic steps on liver
cytosol, and recognized a specific protein needed for SNARE complex formation. Using tandem
mass spectroscopy the protein on the active fraction was identified as being a Heat shock
protein. Each of the bars on figure 2A depicts the recombinant proteins (40g) of each identified
protein which were assayed for Fusion-complex formation activity. Proteins were incubated with
[14C]TAG-loaded hepatic ER (500 ug of protein). (1); Glucose-regulated protein (GRP) /BIP
(2); Heat shock cognate 70 (3); Profilin A (4); and Retinol binding protein 2 (5).
Figure 3 (B) Effect of Hsc70-depleted cytosol on fusion-complex formation:

After determining Hsc-70 as the protein needed for SNARE complex formation, liver cytosol
was immunodepleted of Hsc70 using specific antibody and the immunodepletion was determined
by Western blotting. The immunodepletion of Hsc-70 from the cytosol resulted in 80% reduction
in fusion activity. However after adding the recombinant Hsc-70 to the depleted cytosol the
fusion activity was completely restored. Native cytosol (1); Hsc70 depleted cytosol (2); and
Hsc70-depleted cytosol + recombinant Hsc70 protein (3)
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ER

Cytosol

IP w/ Sec22b

Supernatant

Hsc-70

Figure 4. Co-Immunoprecipitation (Co-IP) with Sec22b antibodies using cytosolic proteins, membrane
probed with Hsc-70

The objective of this experiment was to pull down the SNARE complex and probe the membrane
with Hsc-70 to determine whether Hsc-70 binds to the v-SNARE Sec22b. In order to carry out
this experiment we used 1mg of cytosolic proteins, Sec22b as primary antibody and agarose
beads with anti-mouse. Furthermore, in the ER sample the band at 70Kda indicates the presence
of Hsc-70, also in both the cytosol and supernatant samples but no presence Hsc-70 in the IP
sample signifying no binding Sec22b and Hsc-70 using Cytosol. Finally, the IP sample indicates

	
  

that after developing of 35 minutes, indicates that after developing of 35 minutes, there is a
no prominent band signifying no binding of Hsc-70 and Sec22b.
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ER

Cytosol

IP w/ Sec22b

Supernatant

Sec22b

Figure 5 Co-Immunoprecipitation (Co-IP) with Sec22b antibodies using cytosolic proteins, membrane probed
with Sec22b.

The main objective was to show the presence of Sec22b in the IP sample. First we stripped the
membrane from the Hsc-70 antibody and proceeded to reprobe membrane with Sec22b. The
results in the above figure depict that Sec22b is present at 22kDa in the ER since in functions as
a v-SNARE for ER derived vesicles. In addition, Sec22b is also present in the IP sample at
22kDa however the band present is very light to confirm binding with Hsc-70, therefore to
confirm the binding of Hsc-70 and Sec22b, an IP with Hsc-70 and testing with Sec22b
antibody must be carried out.
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ER

Cytosol

IP w/ Hsc-70

Hsc-70

Figure 6. Co-IP with Hsc-70 antibodies using cytosolic proteins, membrane probed with Hsc-70

The main objective was to prove that the IP of Hsc-70 with cytosol was successful. To carry out
this experiment we stripped the membrane from Sec22b antibody and reprobed with Hsc-70
primary antibody. Furthermore, the results portray bands found at 70kDa for the ER, cytosol and
IP samples. The ER bands shows that there could be binding at the level of the ER, the
cytosol further confirm the presence of Hsc-70 in the cytosol since naturally it is a cytosolic
protein. Likewise, the IP of Hsc-70 sample indicates the existence of Hsc-70 at 70kDa,
which signifies the success of the IP.
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Cytosol 	
  	
  	
  	
  	
  	
  	
  ER

IP w/ Hsc-70	
  

Golgi

Gos28

Figure 7. Co-IP with Hsc-70 antibodies using solubilized cis-Golgi proteins, membrane probed with Gos28

The goal of this experiment was to determine which t- SNAREs bind to Hsc-70 in SNARE
complex formation. For the immunoprecipitation we used cis-Golgi, Hsc-70 as the primary
antibody and secondary antibody anti-mouse agarose beads. Furthermore, the above results
depict that Gos28 binds to HSC-70 since there is a clear bold band that comes up in 28kDa.

IP w/ Hsc-70	
  	
  	
  	
  ER

Cytosol Golgi

Syn5

Figure 8. Co-IP with Hsc-70 antibodies using solubilized cis-Golgi proteins, membrane probed with Syn5

The membrane was stripped from the Gos28 primary antibody and reprobed with Syn5 primary
antibody. The results indicate that Hsc-70 does bind with Syn-5, the t-SNARE on the Golgi
membrane.
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Golgi	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   IP w/ Hsc-70	
  

ER

r-Bet1

Figure 9. Co-IP with Hsc-70 antibodies using solubilized cis-Golgi proteins, membrane probed with r-Bet1

R-Bet-1 is a protein that functions as one of the t-SNARE for the cis-Golgi and forms part of the
SNARE complex with the VTV which is a necessary step for proper delivery of VLDL. In the
above blot we used primary R-Bet-1 with an anti-mouse secondary antibody and found that there
was no binding in the IP sample since there is no band around 18kDa, the molecular weight of RBet1. Finally, the results indicate that r-Bet1 does not bind to Hsc-70

IP w/ Hsc-70	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  ER

Cytosol

Golgi

Sec22b

Figure 10. Co-IP with Hsc-70 antibodies using solubilized cis-Golgi proteins, membrane probed with Sec22b

To further confirm binding of Sec22b and Hsc-70 we reprobed the membrane with Sec22b
primary antibody and the results verify binding of Sec22b and Hsc-70 at the cis-Golgi level,
the IP and ER sample indicate a clear band at 22kDa, the molecular weight of Sec22b. In
addition, there is no band showing up in the cis-Golgi sample since Sec22b is present on the ER
membrane and part of the VTV acting as a v-SNARE.
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ER

Cytosol

IP w/ Hsc-70

Sec22b

Figure 11. Co-IP with Hsc70 antibodies using solubilized ER proteins, membrane probed with Sec22b

To confirm Hsc-70 binding with Sec22b, we co-immunoprecipitated ER with Hsc-70, we proved
the membrane with Sec22b and the results confirm that Sec22b does bind to Hsc-70 at the ER
level. The band is shown at the 22kDa mark in both the ER and the Co-IP with Hsc-70.

ER

Cytosol

IP w/ Hsc-70

Syn5

Figure 12. Co-IP with Hsc70 antibodies using solubilized ER proteins, membrane probed with Syn-5

Syntaxin 5 is a t-SNARE proteins that functions to form the SNARE complex for VTV-Golgi
fusion. However, Syn5 is also a protein that it is found in the ER since it has been found to take
part in ER-Golgi transport of vesicles. Therefore, we tested the Co-IP with Hsc-70 using
solubilized ER proteins with the Syn5 antibody. Conversely the above results indicate that
although Syn5 is present in the ER it does not bind to Hsc70.
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CHAPTER FOUR: DISCUSSION
The present study evaluates the role of the heat shock protein, Hsc70 in SNARE-complex
formation required for docking and fusion of the VTV with the hepatic cis-Golgi. The slowest
step in the transport of VLDL happens in its pathway from the hepatic ER to cis-Golgi, therefore
unraveling the intricate details in which VLDL biogenesis and secretion takes place would put
forth a solution towards the regulation of how VLDL is expelled into the circulatory system.
Briefly, the biogenesis of the VLDL lipoprotein begins in the rough ER in response to the fatty
acid influx, the liver uptakes fatty acids by: chylomicron remnants, through the portal vein,
dietary fat and adipose tissue [2, 3]. The biogenesis of VLDL is broken down into two steps, first
ApoB100- a structural protein necessary for the proper formation of the VLDL is translated in
the rough ER and then translocated to the lumen of the ER where MTP enables the transfer of
lipids to ApoB100, the lipidation of ApoB100 relies on the accessibility of triglycerides in the
ER [10, 28]. The second step constitutes the adding of triglycerides to the primordial poorly
lipidated ApoB100 particle. Although the site of VLDL maturation is subject to debate, data
from Siddiqi et al [14] indicated that the VLDL particle is packed into a specific vesicle- the
VTV which will travel in anterograde fashion and fuse with the cis-Golgi membranes where the
VLDL-ApoB100 will undergo further glycosylation and phosphorylation.
As opposed to the PTV, an ER-derived vesicle with Golgi destination, the VTV
comfortably fits the 100-120 nm VLDL particle and protects the apoB100 protein from
degradation in the cytosol. Additionally, the surface of the VTV concentrates Sec22b that serves
as a v-SNARE and will eventually form a SNAREpin or SNARE complex with GOS28, Syn5
and rBet1 the three t-SNAREs found on the cis-Golgi membrane. The SNAREpin will allow for
the VTV and the cis-Golgi membrane to fuse permitting the release of VLDL into the lumen of
the Golgi [3].
The fusogenic SNARE complex requires cytosolic proteins that will facilitate the
SNARE pairing. After several chromatographic steps on liver cytosol and detailed mass
spectrometry studies it was revealed that heat-shock, Hsc-70 to play a role in the formation of the
SNARE complex [24]. In addition, (Siddiqi et al; unpublished data) have indicated that the
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presence of Hsc-70 is vital for SNARE complex formation thus proper delivery of VLDL.
Experiments have demonstrated that when using Hsc-70 depleted cytosol the fusion-complex
formation is diminished by almost 80 percent, however, when Hsc-70 recombinant protein is
added the complex formation activity is restored (see figure 2,3). Furthermore, in order to
examine how Hsc70 plays a role in SNARE complex formation, we carried out
immunoprecipitaion experiments to identify to which SNARE proteins Hsc-70 binds. Western
blot data suggest that Hsc70 binds to Sec22b at the ER and cis-Golgi level, (see figures 5,10,
11). These data indicate that Hsc-70 could in fact act as a chaperone protein, supporting previous
studies that suggest the involvement of Hsc-70 in ER to Golgi transport. It also supports Hsc-70
established role of serving as a chaperone in the cell [24, 27]. We predict that Hsc-70 binds to
Sec22b, the v-SNARE on the VTV in the ER and brings the VTV into close proximity with the tSNAREs allowing the SNARE complex to form. Interestingly, figure 12 shows the presence of
Syn5 in the ER sample, studies done by Dasher and Rowe [29, 30] indicate that although Syn5
has been known to be a t-SNARE, it has an isoform that has been shown to possibly serve as a
potential regulator for ER to Golgi transport [31]. In addition, (figure 7, 8 and 9) suggest that
Hsc-70 binds to GOS28, Syn5 but not rBet1; its role here continues to be enigmatic. Some
possibilities arise; one is that since the SNARE complex forms through the zippering action of
the contributing SNARE motifs, the bound chaperone might act to promote the assembly of the
SNAREs so that the α- helical coiled structure forms, studies from the Hay group show that this
assembly does not require ATP, consistent with our data that docking, the step before fusion is
ATP – independent. Other possibility is that Hsc-70 might act to provide the energy necessary so
fusion can occur. In addition, the SNARE complex is specific for each transport step and is also
thermodynamically and kinetically stable, therefore the dissociation of the complex requires ATP
hydrolysis; we believe Hsc-70 can act as an ATPase an action seen by Hsc70 in other trafficking
pathways with clathrin and synaptic vesicles [32, 33]. Ultimately, understanding the role Hsc-70
plays in the transport of VTVs from the ER to the Golgi could in fact offer further dissection of
how VLDL is secreted into the bloodstream.
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Figure 13. Intracellular VLDL transport

The assembly of VLDLs occurs in the lumen of the endoplasmic reticulum (ER). After their
biogenesis in the ER lumen, VLDLs are packaged into specialized vesicles known as VLDL
transport vesicles (VTVs). The average diameter of the VTVs is ∼110 nm, which is sufficient to
enclose VLDL-sized particles. VTVs bud off the ER membrane and move to and fuse with the
cis-Golgi, delivering their VLDL cargo to the Golgi lumen. Nascent proteins are transported
from the ER to the Golgi protein transport vesicles (PTVs). Their size ranges between ∼55 and
70 nm. Biogenesis of both VTVs and PTVs from the ER membrane requires coat protein
complex II (COPII) machinery. VTVs are, however, different from PTVs in their size, buoyant
density, protein composition and require a unique set of SNARE proteins for fusion-complex
formation.
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